The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV‐1 Infection in a Phase 3 HIV‐1 Preventive Vaccine Trial
Open accessAbstract
BACKGROUND: An objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein 120 (rgp120) antigens was to assess correlations between antibody responses to rgp120 and the incidence of HIV-1 infection. METHODS: Within the randomized trial (for vaccinees, n=3598; for placebo recipients, n=1805), binding and neutralizing antibody responses to rgp120 were quantitated. A case-cohort design was used to study correlations between antibody levels and HIV-1 incidence. RESULTS: Peak antibody levels were significantly inversely correlated with HIV-1 incidence. The relative risk (RR) of infection was 0.63 (95% confidence interval, 0.45-0.89) per log(10) higher neutralization titer against HIV-1(MN), and the RRs of infection for second-, third-, and fourth-quartile responses of antibody blocking of gp120 binding to soluble CD4 versus first-quartile responses (the lowest responses) were 0.35, 0.28, and 0.22, respectively. CONCLUSIONS: Despite inducing a complex, robust immune response, the vaccine was unable to reduce the incidence of HIV-1. Two interpretations of the correlative results are that the levels of antibodies (i) caused both an increased (low responders) and decreased (high responders) risk of HIV-1 acquisition or (ii) represented a correlate of susceptibility to HIV-1 but had no causal effect on susceptibility. Although the data cannot definitively discriminate between these 2 explanations, (ii) appears to be more likely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
The role of a mutant CCR5 allele in HIV–1 transmission and disease progression
Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., et al. (1996) · Nature Medicine · doi:10.1038/nm1196-1240 · Cited by 1,358
The antigenic structure of the HIV gp120 envelope glycoprotein
Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A., & Sodroski, J. G. (1998) · Nature · doi:10.1038/31514 · Cited by 1,203
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., & Eichberg, J. W. (1990) · Nature · doi:10.1038/345622a0 · Cited by 590
Self-citationKliks, S. C., Nisalak, A., Brandt, W. E., Wahl, L., & Burke, D. S. (1989) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1989.40.444 · Cited by 517
Self-citationResistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
Fowke, K. R., Nagelkerke, N. J., Kimani, J., Simonsen, J. N., Anzala, A. O., Bwayo, J. J., MacDonald, K. S., Ngugi, E. N., & Plummer, F. A. (1996) · The Lancet · doi:10.1016/s0140-6736(95)12269-2 · Cited by 463
Antibody-Enhanced Infection by HIV-1 Via Fc Receptor-Mediated Entry
Takeda, A., Tuazon, C. U., & Ennis, F. A. (1988) · Science · doi:10.1126/science.2972065 · Cited by 460
Pantaleo, G., & Koup, R. A. (2004) · Nature Medicine · doi:10.1038/nm0804-806 · Cited by 444
Rowland-Jones, S. L., Dong, T., Fowke, K. R., Kimani, J., Krausa, P., Newell, H., Blanchard, T., Ariyoshi, K., Oyugi, J., Ngugi, E., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4314 · Cited by 421
ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION
Robinson, W. E., Montefiori, D., & Mitchell, W. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91657-1 · Cited by 358
Antibody-Dependent Enhancement of Infection and the Pathogenesis of Viral Disease
Morens, D. M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.3.500 · Cited by 317
Exposure stratified case-cohort designs.
Borgan, Ø., Langholz, B. M., Samuelsen, S. O., Goldstein, L. J., & Pogoda, J. M. (2000) · Lifetime Data Analysis · doi:10.1023/a:1009661900674 · Cited by 286
Persistent GB Virus C Infection and Survival in HIV-Infected Men
Williams, C. F., Klinzman, D., Yamashita, T. E., Xiang, J., Polgreen, P. M., Rinaldo, C., Liu, C., Phair, J., Margolick, J. B., Zdunek, D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030107 · Cited by 269
Kaul, R., Rowland-Jones, S. L., Kimani, J., Dong, T., Yang, H.-B., Kiama, P., Rostron, T., Njagi, E., Bwayo, J. J., MacDonald, K. S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10714 · Cited by 223
Combining Dependent Tests with Incomplete Repeated Measurements
Wei, L. J., & Johnson, W. E. (1985) · Biometrika · doi:10.2307/2336088 · Cited by 188
Polack, F. P., Hoffman, S. J., Crujeiras, G., & Griffin, D. E. (2003) · Nature Medicine · doi:10.1038/nm918 · Cited by 161
Homsy, J., Meyer, M., & Levy, J. A. (1990) · Journal of Virology · doi:10.1128/jvi.64.4.1437-1440.1990 · Cited by 155
Mascola, J. R., Mathieson, B. J., Zack, P. M., Walker, M. C., Halstead, S. B., & Burke, D. S. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.1175 · Cited by 96
Self-citationAdvancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
Francis, D. P., Gregory, T. J., McElrath, M. J., Belshe, R. B., Gorse, G. J., Migasena, S., Kitayaporn, D., Pitisuttitham, P., Matthews, T. J., Schwartz, D. H., et al. (1998) · PubMed · Cited by 73
Self-citationRichardson, J. P., Moraillon, A., Baud, S., Cuisinier, A., Sonigo, P., & Pancino, G. (1997) · Journal of Virology · doi:10.1128/jvi.71.12.9640-9649.1997 · Cited by 72
Harro, C. D., Judson, F. N., Gorse, G. J., Mayer, K. H., Kostman, J. R., Brown, S. J., Koblin, B. A., Marmor, M. F., Bartholow, B. N., & Popovic, V. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000122983.87519.b5 · Cited by 58
Self-citationHuman HIV Vaccine Trials: Does Antibody-Dependent Enhancement Pose a Genuine Risk?
Burke, D. S. (1992) · Perspectives in biology and medicine · doi:10.1353/pbm.1992.0048 · Cited by 57
Self-citationResistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2
Amad, Z., MURTHY, K. K., Higgins, K. W., Cobb, E. K., Haigwood, N. L., Levy, J. A., & Steimer, K. S. (1995) · AIDS · doi:10.1097/00002030-199512000-00003 · Cited by 49
Persistent alterations in the T-cell repertoires of HIV-1-infected and at-risk uninfected men
Killian, M. S., Monteiro, J., Matud, J. L., Hultin, L. E., Hausner, M. A., Yang, O. O., Gregersen, P. K., Detels, R., Giorgi, J. V., & Jamieson, B. D. (2004) · AIDS · doi:10.1097/00002030-200401230-00004 · Cited by 26
Cited by
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Self-citationImmune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Self-citationThe rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
Sanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., Choopanya, K., & Bangkok Vaccine Evaluation Group (2006) · The Journal of Infectious Diseases · doi:10.1086/508748 · Cited by 847
Self-citation
Metadata
- Authors
- Gilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V., Self, S. G., Sinangil, F., Burke, D., & Berman, P. W.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03
- Volume
- 191
- Issue
- 5
- Pages
- 666-677
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2138957964
- Cited by
- 355
- References
- 25
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.